A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Basic science
Enrollment
14actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-21 | actual | When the study began enrolling |
| Primary completion | 2025-05-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-12 | actual | The whole study's end, after follow-up |
| First posted | 2025-03-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Adults
Interventions
- Drug: PF-07220060
- Drug: Carbamazepine ER Tablet
Primary outcomes
what the primary-completion date above is the date OFPlasma PF-07220060 Maximum Observed Plasma Concentration (Cmax)
measured Pre-dose, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 and 120 hours post-dose.
Plasma PF-07220060 Area under the plasma concentration versus time curve (AUC)
measured Pre-dose, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 and 120 hours post-dose.
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed